GERALDINE LE DUC
CEO/cofondatrice
NH TherAguix
Grenoble, France
4 visites de profilIntervenantLes non-membres - avec rendez-vous B2B
Chercheur (PhD, HDR, 120 articles, 7 brevets) CEO/cofondatrice NHT TherAguix (€30M dilutifs, 20 FTE, Phase 2) Presidente Therasonic Senior Advisor Accélérateur
Mon organisation
NH TherAguix , a Phase 2 biotech company, has developed an innovative nano drug AGuIX® to improve cancer treatment by radiotherapy to treat tumours and metastases. Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential. AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA). NH TherAguix was established in 2015 after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radioenhancement effect. Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.
Sessions d'intervenants 1
mardi 14 octobre 2025
14:30 - 16:30
Table ronde 5 | De l'idée labo à la solution santé : mobiliser les expertises pour accélérer le développement des start-ups en santé
Lieu :Salle de commission 8/9Track :Tables rondes
soutenue par le Pôle Universitaire d'Innovation Grenoble Alpes